New antifungal agents and preparations

International Journal of Antimicrobial Agents

Volumn 16, Issue 2, 2000, Pages 147-150

  De Pauw, Ben E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drugs; Fungal infections; Patients

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICONAZOLE; POSACONAZOLE; SORDARIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CANDIDA; CANDIDIASIS; HUMAN; LUNG ASPERGILLOSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033775843     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00221-1     Document Type: Article

References (11)

1. Current role of therapy with amphotericin B
2. Oral azole drugs as systemic antifungal therapy
3. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
4. Current and emerging azole antifungal agents
5. International conference for the development of a consensus on the management and prevention of severe candidal infections
6. Use of amphotericin B with azole antifungal drugs: what are we doing?
7. Lipid formulation of amphotericin B: clinical efficacy and toxicities
8. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases
9. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
10. An EORTC multicenter randomised trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
11. Systemically administered antifungal agents